KEGG   DRUG: D05446Help
Entry
D05446                      Drug                                   

Name
Pertuzumab (genetical recombination) (JAN);
Pertuzumab (USAN/INN);
Perjeta (TN)
Product
Activity
Antineoplastic [DS:H00031]
Remark
Therapeutic category: 
ATC code: 
Comment
Monoclonal antibody
Target
ERBB2 tyrosine kinase [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa04020  Calcium signaling pathway
hsa04510  Focal adhesion
hsa04520  Adherens junction  
 
Interaction
Genomic biomarker: HER2 [HSA:2064]
Drug interaction
Structure map
Antineoplastics - protein kinases inhibitors
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D05446  Pertuzumab (genetical recombination) (JAN); Pertuzumab (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC13 Pertuzumab
      D05446  Pertuzumab (genetical recombination) (JAN); Pertuzumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Receptor tyrosine kinase
   RTK class I (EGF receptor family)
    ERBB2 tyrosine kinase [HSA:2064] [KO:K05083]
     Pertuzumab
      D05446  Pertuzumab (genetical recombination) (JAN); Pertuzumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
380610-27-5
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system